Understanding Hypercoagulability with Nephrotic Syndrome: How the Clot Thickens
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Kitlinski M, Heleniak Z, Debska-Slizien A Ren Fail. 2025; 47(1):2441392.
PMID: 39744976 PMC: 11703376. DOI: 10.1080/0886022X.2024.2441392.
Membranous nephropathy: pathogenesis and treatments.
Wang M, Yang J, Fang X, Lin W, Yang Y MedComm (2020). 2024; 5(7):e614.
PMID: 38948114 PMC: 11214595. DOI: 10.1002/mco2.614.
References
1.
Barbour S, Greenwald A, Djurdjev O, Levin A, Hladunewich M, Nachman P
. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2011; 81(2):190-5.
DOI: 10.1038/ki.2011.312.
View
2.
Abdelghani E, Waller A, Wolfgang K, Stanek J, Parikh S, Rovin B
. Exploring the Role of Antithrombin in Nephrotic Syndrome-Associated Hypercoagulopathy: A Multi-Cohort Study and Meta-Analysis. Clin J Am Soc Nephrol. 2023; 18(2):234-244.
PMC: 10103265.
DOI: 10.2215/CJN.0000000000000047.
View
3.
Cremoni M, Brglez V, Perez S, Decoupigny F, Zorzi K, Andreani M
. Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses. Front Immunol. 2020; 11:574997.
PMC: 7725714.
DOI: 10.3389/fimmu.2020.574997.
View
4.
Thaler E, Balzar E, Kopsa H, Pinggera W
. Acquired antithrombin III deficiency in patients with glomerular proteinuria. Haemostasis. 1978; 7(5):257-72.
DOI: 10.1159/000214268.
View
5.
Mahmoodi B, ten Kate M, Waanders F, Veeger N, Brouwer J, Vogt L
. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2007; 117(2):224-30.
DOI: 10.1161/CIRCULATIONAHA.107.716951.
View